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Abstract: It is unclear how well currently available risk scores predict 
cardiovascular disease (CVD) risk in low-income and middle-income 
countries. We aim to compare the American College of Cardiology/American 
Heart Association (ACC/AHA) Pooled Cohort risk equations (ACC/AHA 
model) with 6 other CVD risk tools to assess the concordance of predicted 
CVD risk in a random sample from 5 geographically diverse Peruvian 
populations. We used data from 2 Peruvian, age and sex-matched, population-
based studies across 5 geographical sites. The ACC/AHA model were 
compared with 6 other CVD risk prediction tools: laboratory Framingham risk 
score for CVD, non-laboratory Framingham risk score for CVD, Reynolds 
risk score, systematic coronary risk evaluation, World Health Organization 
risk charts, and the Lancet chronic diseases risk charts. Main outcome was 
in agreement with predicted CVD risk using Lin’s concordance correlation 
coefficient. Two thousand one hundred and eighty-three subjects, mean age 
54.3 (sD ± 5.6) years, were included in the analysis. Overall, we found poor 
agreement between different scores when compared with ACC/AHA model. 
When each of the risk scores was used with cut-offs specified in guidelines, 
ACC/AHA model depicted the highest proportion of people at high CVD risk 
predicted at 10 years, with a prevalence of 29.0% (95% confidence interval, 
26.9–31.0%), whereas prevalence with World Health Organization risk 
charts was 0.6% (95% confidence interval, 0.2–8.6%). In conclusion, poor 
concordance between current CVD risk scores demonstrates the uncertainty 
of choosing any of them for public health and clinical interventions in Latin 
American populations. There is a need to improve the evidence base of risk 
scores for CVD in low-income and middle-income countries.
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Increasing rates of cardiovascular diseases (CVD) in low-income and middle-income countries (LMIC), and occurring at younger ages 
than seen in high-income countries, urge the need for action.1–3 Many 
public health interventions have arisen to prevent CVD in LMIC, 
including policies to reducing tobacco usage and salt intake. CVD pre-
vention at the individual level remains necessary and cost-effective.4,5 
The World Health Organization (WHO) recommends using CVD 
risk assessment tools to direct evidence-based medication, including 
aspirin and statin therapy, for primary prevention of asymptomatic 
individuals in relation to any given level of CVD risk.6 In addition, 
recent evidence augments these recommendations by showing that 
blood pressure lowering protects patients according to their CVD 
risk status. Because larger benefits were observed among groups with 
greater baseline CVD risk, risk equations appear well positioned to 
also inform blood pressure-lowering treatment decisions.7
However, to date, no CVD risk assessment tool has been 
developed using longitudinal data from LMIC. The likelihood of this 
occurring in the near term is very small. The most recent comprehen-
sive systematic pooling of worldwide longitudinal cardiometabolic 
data, which analyzed 96 cohorts totaling 1.8 million subjects,8 looked 
prospectively to the relationship and burden of 2 important out-
comes, ie, coronary heart disease (CHD) and stroke. Yet, out of the 
97 studies, only one was from the south American region (Brazil).8 
In this context, existing CVD risk assessment tools do fulfill a role 
on informing day-to-day clinical practice in most LMIC. However, 
frontline clinical workers and policy makers in LMIC settings do not 
have sufficient guidance on which tool to use better.
Although the Framingham Heart study resulted in the first car-
diovascular risk prediction model, the Framingham risk score (FRs), 
additional risk scores have been developed accounting for novel CVD 
risk factors and different populations.9 Based on the FRs, the third 
Adult Treatment Panel incorporated risk stratification in determining 
eligibility for statin therapy.10 However, the FRs risk assessment tool 
used in the third Adult Treatment Panel focuses in predicting 10-year 
risk of coronary events, defined as nonfatal myocardial infarction 
(MI) and CHD-related mortality. In 2014, the American College of 
Cardiology/American Heart Association (ACC/AHA) introduced the 
Pooled Cohort risk equations (ACC/AHA model),11 which used data 
from several community-based Us-specific cohort studies to develop 
new sex-specific and race-specific equations to predict 10-year risk 
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for atherosclerotic CVD events, including nonfatal MI, CHD-related 
mortality, and stroke.12 The ACC/AHA model has been validated in a 
separate UsA cohort and demonstrated good calibration for the pop-
ulation it was designed.13 However, when compared with a European 
cohort, these models showed poor calibration and moderate to good 
discrimination.14 It is unclear how well the currently available risk 
scores assess or predict CVD risk in LMIC and in Latin American 
settings. With the exception of the FRs, most of CVD risk assess-
ment tools lack external validation in LMIC.9
We aimed to compare the ACC/AHA model with 6 other CVD 
risk tools to assess the concordance of predicted CVD risk in a ran-
dom sample from 5 geographically diverse Peruvian populations. 
Moreover, to estimate the clinical impact of adopting the use of each 
risk assessment tool in Peru, we compared the proportion of individ-
uals classified as high CVD risk according to the established cut-offs 
for each risk assessment tool.
METHODS
We used secondary cross-sectional data from 2 Peruvian popu-
lation-based epidemiological studies: the PERU MIGRANT study15 
and the CRONICAs cohort study.16 The former, n = 989, described 
the CVD risk profiles in 3 Peruvian populations: Ayacucho (rural, 
highlands), Lima (urban, sea level), and rural-to-urban migrants in 
Lima. The CRONICAs cohort study has been designed as a prospec-
tive study of cardiopulmonary risk factors in over 3000 individuals 
in 4 Peruvian populations: Lima (highly urban, sea level), Tumbes 
(semiurban, sea level), rural, and urban Puno (highlands). In this 
study, we used the baseline data from CRONICAs. Both studies used 
a structured questionnaire and collected anthropometric and labora-
tory data15,16 required for CVD risk estimation (Table 1).
CVD Risk Prediction Tools
We compared the ACC/AHA model with 6 other CVD risk 
prediction tools: laboratory Framingham risk score (FRs-lipids),17 
non-laboratory Framingham risk score using body mass index (FRs-
non-lab),17 Reynolds risk score (RRs),19,20 systematic coronary risk 
evaluation (sCORE),21 WHO’s Risk Chart for the Americas Region 
(WHO/International society of Hypertension),18 and the risk chart 
developed by the Lancet chronic diseases group.22 The last 2 risk 
models provide a chart-based categorization of high risk and were 
included in our analyses because they were created specifically for 
use in developing countries.
Statistical Analysis
Participants with known CVD, MI, or stroke were excluded 
from our analysis. To enable comparisons across scores, we restricted 
our analysis to participants within 45–65 years age range.
Continuous and categorical 10-year CVD risks were calculated, 
using the risk algorithms or charts, where available. Further details 
about each risk prediction tools included in this study are shown in 
Table 1. We assessed agreement in pair-to-pair analyses against the 
ACC/AHA model. For those scores where risk equations were avail-
able, we calculated predicted risk as a continuous variable and used 
TAblE 1. Features of Cardiovascular Risk Prediction Tools
Location/Studies for 
Predictions
Age  
Range Gender Variables Outcomes
FRs, Global CVD17: 2 
versions used, FRs- 
lipids and FRs-non-lab 
(non-laboratory)
Framingham, MA, UsA 30–74 Men and women Age, gender, sBP, HTN 
treatment, TC, HDL-c, 
DM, smoking*
10-year risk of coronary death, MI, coronary 
insufficiency, angina, ischemic stroke, 
hemorrhagic stroke, transient ischemic 
attack, peripheral artery disease, heart 
failure (continuous)
ACC/AHA model11 CARDIA, Framingham, 
ARIC, CHs, UsA
40–79 Men and women Age, gender, sBP, HTN 
treatment, TC, HDL-c, 
DM, smoking
10-year risk of fatal or non-fatal CHD, fatal 
or non-fatal stroke (continuous)
World Health 
Organization Risk 
Chart (WHO/IsH)18
According to Regions. 
Acronym for Americas: 
AMR
40–79 Men and women Age, gender, smoking, 
sBP, TC, DM
10-year risk of fatal or non-fatal MI or stroke 
(categorical)
RRs19,20 Multicenter, UsA
Physician’s Health study, 
Women’s Health study
45–80 Both (men and 
women but 
with 2 different 
datasets)
Age, tobacco use, sBP, 
FH, HDL-c, hsCRP, 
TC; HbA1c, parental 
history of MI <60 
years.
10-year risk of fatal or non-fatal CHD, 
fatal or non-fatal stroke, coronary 
revascularization (continuous)
sCORE project risk score 
(sCORE),21 4 versions 
used: High-risk and 
low-risk countries, with 
and without HDL-c.
12 European cohorts 40–65 Men and women Age, gender, sBP, TC, 
HDL-c, smoking, 
region
10-year risk of CHD death or stroke death 
(continuous)
Risk Chart developed by 
LCD group22
simulated population- 
specific predictions
40–80 Men and women Age, sex, sBP, tobacco 
use, diabetes (with 
formula), BMI (with 
charts)
10-year risk of fatal or non-fatal CHD or 
stroke (categorical)
* smoking profile, not smoking status, during the last year was defined by the answers “occasionally” or “daily” to the question “Currently, do you smoke?” This decision was 
made to accommodate different period requirements, last year versus last month, of different risk scores.
sBP, systolic blood pressure; HTN, hypertension; TC, total cholesterol; HDL-c, high-density lipoprotein cholesterol; DM, diabetes mellitus; FH, family history; hsCRP, high-
sensitivity C-reactive protein; BMI, body mass index; LCD, Lancet Chronic Diseases.
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Lin’s concordance correlation coefficient (CCC).23 CCC quantifies 
the agreement ranging from −1 to 1, with perfect agreement at 1. CCC 
has the following classification according to strength of agreement 
(theoretical): >0.99 almost perfect, 0.95–0.99 substantial, 0.90–0.95 
moderate, and <0.90 poor.24 Empirical cut-offs for delimiting optimal 
concordance, where CCC values obtained after contrasting different 
versions of the same CVD risk scores, ie, FRs-Lipids versus FRs-
non-lab; sCORE-1 versus sCORE-2, and sCORE-3 versus sCORE-
4, are shown separately in supplemental Tables 1 and 2 (supplemental 
Digital Content, http://links.lww.com/HPC/A198).
We calculated percentages of people at high CVD risk for 
every score, using the established cut-off points in their original 
reports: ACC/AHA model ≥7.5%, FRs ≥20%, RRs ≥20%, Lancet 
Chronic Diseases ≥15%, sCORE ≥5%, and WHO/International 
society of Hypertension ≥20%. Furthermore, a subsequent analysis 
was conducted using a similar definition of high CVD risk at 20% 
across all tools for visual assessment on their percentages of people 
classified as high risk. Additional agreement evaluation between 
dichotomous variables of CVD risk was performed using Kappa 
index (supplemental Table 3, supplemental Digital Content, http://
links.lww.com/HPC/A198).
sTATA 12 software (sTATA Corp, College station, TX, UsA) 
was used for analysis. In all estimations 95% confidence intervals 
were calculated.
RESUlTS
Participant’s Characteristics
The combined datasets included a total of 4604 participants. 
The following were excluded: 184 participants with prior episodes of 
MI or stroke and 2165 participants outside of the scores’ age range. 
To avoid individual-level data duplication, 72 records from the PERU 
MIGRANT study were also removed, as these subjects also took part in 
the CRONICAs Cohort study. Therefore, data from a total of 2183 par-
ticipants, mean age 54.3 (sD ± 5.6) years, were included in the analysis.
Table 2 shows study populations’ characteristics. Across sites, 
most of the participants reported a monthly family income of $196 
UsD or less, except in Tumbes and urban Puno where the majority 
of participants reported a monthly income between $197 and $535 
UsD. Both rural sites, Ayacucho and rural Puno, had the lowest body 
mass index and highest mean high-density lipoprotein cholesterol. 
Relative to the other study sites, mean glucose was much higher in 
Tumbes and lowest in Ayacucho, and these 2 sites had higher mean 
systolic blood pressures.
Agreement between Risk Scoring Tools
Agreement between CVD risks in continuous format (Table 3) 
was evaluated using CCC. Overall, when scores were compared with 
ACC/AHA model, in the total sample as well as specific sites, we 
found poor CCC agreement values. The highest agreement was 
observed in comparisons between ACC/AHA model and FRs-non-
lab (40%) and FRs-Lipid scores (44%). The lowest agreement was 
observed between ACC/AHA model and sCORE-3 and sCORE-4, 
with 14% and 17%, respectively.
Agreement between risk scores also differed in magnitude 
by study sites. The highest agreement values were observed in rural 
Ayacucho, 74% between ACC/AHA model and FRs-non-lab, and in 
rural Puno, 77% between ACC/AHA model and RRs.
Prevalence of High CVD Risk as Per Recommended 
Guidelines
Figure 1 shows the prevalence of high CVD risk status in 
the pooled dataset as per recommendations by each risk assessment 
tool’s original publication. ACC/AHA model depicted the highest 
proportion of people at high CVD risk predicted at 10 years, with a 
prevalence of 29.0% (95% confidence interval, 26.9–31.0%). When 
analyzed by specific study sites, ACC/AHA model also had the high-
est prevalence of individuals at high CVD risk relative to other scores 
(supplemental Fig. 1, supplemental Digital Content, http://links.
lww.com/HPC/A198). supplemental Table 3 (supplemental Digital 
Content, http://links.lww.com/HPC/A198) shows Kappa for agree-
ment between categories of predicted high risk by scores, with find-
ings indicating poor agreement.
Using a similar definition of high risk at 20% across all tools, 
FRs yielded the highest overall prevalence of high-risk status (Fig. 2). 
This pattern was the same across subgroup populations, except in 
Ayacucho where high-risk status was much higher with ACC/AHA 
model (supplemental Fig. 2, supplemental Digital Content, http://
links.lww.com/HPC/A198).
DISCUSSION
This study compares 6 CVD risk assessment tools in a pooled 
dataset with different Peruvian populations, representing low-
income communities in diverse geographical settings, ie, urban and 
rural, coastal and mountainous areas. Poor agreement was found 
for interscore agreement evaluating CVD risk in 10 years. If these 
risk assessment tools were to be applied following their respective 
guidelines there would be wide variation in the proportion of groups 
classified as high risk for CVD. A remarkable high number of people 
would be eligible to initiate pharmacological therapy according to 
our results. Our study provides insights about the applicability of 
CVD high-risk recommendations for LMIC contexts by using real 
data across a diversity of settings, including poor overlap between 
risk assessment tools, which signals to major discrepancies that merit 
careful attention.
Clinical and preventive usefulness can be drawn from our 
results. We found poor agreement between the newest ACC/AHA 
model and other available tools. Moreover, there is huge variation 
between the proportions of the total population classified as high-risk 
by each risk assessment tool, potentially impairing recommendations 
for CVD prevention at the individual level. These findings limit the 
utility of risk prediction scores for public health and health systems 
planning, particularly in resource-limited settings. In these countries, 
further economic studies may be needed to assess cost-effectiveness 
of risk prediction as primary prevention.25
Variations observed in risk-score agreement between differ-
ent Peruvian sub-populations may be explained by differences in 
baseline predictors’ profiles. The 2 rural sites in our study, Puno and 
Ayacucho, had different proportions of high risk as determined by 
ACC/AHA model. These discrepancies were also appreciated in a 
discordance between which individuals were classified as high risk 
by each risk assessment tool. Given the rise of noncommunicable 
diseases in LMIC, further calibration and validation of these tools are 
needed in such settings, and longitudinal studies could help to clear 
this cloudy panorama.26
In line with Krumholz et al’s27 reflections, our study also raises 
substantial concerns about the generalizability of the risk equations 
and also raises the question of whether a threshold for treatment, 
which is admittedly arbitrary and is imbued with values about what 
level of risk is worth treating, is relevant to all countries. Given 
WHO’s recommendations of using risk assessment scores to deter-
mine eligibility for evidence-based therapy, including statin therapy, it 
is necessary to have accurate and precise CVD risk assessment tools. 
The relevance of CVD risk assessment is compounded by increas-
ing interest in polypills—low-dose combinations of blood-pressure 
lowering, cholesterol lowering, and antiplatelet medications—as a 
form of risk reduction for individuals with globally increased high 
risk rather than interventions tailored to specific risk factor control.28
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Using hypothetical data applied to 25 different risk calculators, 
Allan et al29 also found poor agreement, in the order of 67%, similar 
to our study, highlighting the need to calibrate CVD risk assessment 
models to every population when applying clinical guidelines for 
pharmacological therapy. Current risk-scoring strategies are limited 
to UsA and European populations,30 and the INTERHEART modifi-
able risk score, originated from multi-country cross-sectional data, is 
restricted to the prediction of MI.31 Although FRs has been validated 
for diverse Us ethnic groups,32 it has also been demonstrated that FRs 
is not stable in predicting risk, overestimates and underestimates, in non-
UsA groups.26,33–36 The ACC/AHA model has been tested against Us 
cohorts showing discrepancies.13,37,38 similarly, the ACC/AHA model 
was shown to yield poor calibration against FRs-lipids and sCORE in 
the Rotterdam cohort study.14 Although our pooled dataset does not have 
10-year follow-up to externally validate any of the risk assessment mod-
els, the variability in risk prediction demonstrated in our study highlights 
the need to externally validate CVD risk assessment models in LMIC.
Populations from different geographical and epidemiological 
profiles enrich the value of our study, including rural, urban, lowland 
and high altitude sites, much common across Latin America. some 
limitations deserve consideration. Not all tool’s equations were avail-
able, thus chart-based scores did not provide risk assessments as a 
continuous variable, yet in our analysis we included the most com-
monly used risk scores. Another limitation that affects our compara-
bility arises from differences in the definitions used in risk scores’ 
predictors and outcomes. For example, WHO and sCORE address 
CVD-related mortality, whereas the ACC/AHA model focuses on 
fatal and nonfatal atherosclerotic CVD; however, we would have 
expected a higher proportion of overlapping between tools because 
mortality is included in ACC/AHA model. Also, we are cognizant 
that the comparison of yields using different cut-offs, as per cur-
rent recommended guidelines, is limited. The reason for doing this 
assessment is that most healthcare providers will not necessarily be 
aware of the technical and modeling details behind a “10-year high-
risk” label that guidelines tend to “have a paternalistic tone [and] 
tell physicians what should be done”27 and, in the absence of locally 
TAblE 3. Agreement Between CVD Risk Prediction Tools, Calculated as Continuous Risk
CVD Risk Scores
Rho (Lin’s Concordance Correlation Coefficient)
Global
Ayacucho 
(Rural)
Lima  
(Urban)
Puno  
(Rural)
Puno  
(Urban)
Tumbes 
(Urban)
n Rho n Rho n Rho n Rho n Rho n Rho
Comparison between scores
  ACC/AHA model vs. FRs-non-lab 1749 0.40 44 0.74 692 0.50 273 0.40 245 0.29 495 0.24
  ACC/AHA model vs. FRs-lipids 1749 0.44 44 0.58 692 0.53 273 0.49 245 0.35 495 0.32
  ACC/AHA model vs. RRs 1767 0.38 74 0.22 772 0.33 238 0.77 208 0.59 475 0.51
  ACC/AHA model vs. sCORE-1 1923 0.19 83 0.18 827 0.16 273 0.44 245 0.39 495 0.29
  ACC/AHA model vs. sCORE-2 1913 0.22 78 0.19 822 0.18 273 0.46 245 0.49 495 0.38
  ACC/AHA model vs. sCORE-3 1730 0.14 44 0.12 673 0.11 273 0.22 245 0.20 495 0.16
  ACC/AHA model vs. sCORE-4 1730 0.17 44 0.14 673 0.13 273 0.24 245 0.25 495 0.21
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FIGURE 1.  Proportion of high-risk individuals using guide-
lines’ recommended cut-off levels: ACC/AHA model, 29.0% 
[95% confidence interval (CI), 26.9–31.0%]; FRS-non-lab, 
15.1% (95% CI, 13.4–16.8%); FRS-lipids, 13.7% (95% CI, 
12.1–15.3%); RRS, 1.6% (95% CI, 1.1–2.2); WHO/ISH, 0.6% 
(95% CI, 0.2–8.6%); SCORE-1, 7.5% (95% CI, 6.4–8.7%); 
SCORE-2, 8.9% (95% CI, 7.6–10.2%); SCORE-3, 1.5% (95% 
CI, 0.9–2.1); SCORE-4, 1.8% (95% CI, 1.2–2.4); Lancet 
Chronic Diseases, 1.1% (95% CI, 0.6–1.5).
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FIGURE 2.  Proportion of high-risk individuals using a uniform 
20% high-risk cut-off level: ACC/AHA model, 6.6% (95% 
CI, 5.5–7.7%); FRS-non-lab, 15.1% (95% CI, 13.4–16.8%); 
FRS-lipids, 13.7% (95% CI, 12.1–15.3%); RRS, 1.6% (95% 
CI, 1.1–2.2); WHO/ISH, 0.6% (95% CI, 0.2–8.6%); SCORE-
1, 0.2% (95% CI, 0–0.3%); SCORE-2, 0.3% (95% CI, 0.1–
0.5%); SCORE-3, 0%; SCORE-4, 0%.
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available guidelines, they will likely drive practitioners’ prescription 
practices, misassembling level of risk with the consequent overtreat-
ment of people with low level of risk. Therefore, our work signals 
salient differences and poor agreements that in turns calls for more 
education around the usage of risk prediction tools in LMIC together 
with the need to advance the development of LMIC-specific valida-
tion efforts.
In summary, we have shown poor agreement when available 
scores were compared with the newly released ACC/AHA model. 
We have also shown that in Peruvian population, a high proportion of 
individuals would be classified into high CVD risk category. These 
findings emphasize the uncertainty of choosing any of these tools, 
into both clinical and public health fields, in LMIC realities. Our 
work signals to a major and urgent need to improve the evidence base 
for the development and appropriate use of appropriate risk scores 
for CVD in LMIC.
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